Clinical trials · Boston, MA
Solid Tumor, Adult clinical trials in Boston
We’re tracking 51 recruiting solid tumor, adult studies with a site in or near Boston — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Boston
- NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Boston, MassachusettsAges 18–75 - NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Boston, MassachusettsAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
Boston, MassachusettsAges 6 months–25 years - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Boston, MassachusettsAges 18 years+ - NCT07226349RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
Boston, MassachusettsAges 18 years+ - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
Boston, MassachusettsAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Boston, MassachusettsAges 18 years+ - NCT07383506RecruitingPhase 1
Study of a targeted pill for PIK3CA-mutated advanced cancers
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Boston, MassachusettsAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Boston, MassachusettsAges 8 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Boston, MassachusettsAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Boston, MassachusettsAges 18 years+ - NCT07128303RecruitingPhase 1
Study of a new drug for advanced solid tumors with a specific genetic feature
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT05007782RecruitingPhase 1
Testing a new immune drug for advanced solid tumors
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
Boston, MassachusettsAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06265688RecruitingPhase 1
First study of CX-2051 for advanced solid tumors
This study is testing a new drug called CX-2051 for people with advanced solid tumors that have not responded to standard treatments. The drug is a type of targeted therapy that delivers chemotherapy directly to cancer cells, and the goal is to see if it is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other solid tumors
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06532565RecruitingPhase 1
Study of GS-2121 alone or with other drugs for advanced solid tumors
This trial tests a new drug, GS-2121, given alone or with other therapies, for adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Boston, MassachusettsAges Any age - NCT06451497RecruitingPhase 1
Testing ZM008 alone and with toripalimab for advanced cancers
This trial tests a new drug called ZM008, which targets a protein on some cancer cells, first alone and then combined with another drug, toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments.
Boston, MassachusettsAges 18 years+
Hear when a new Solid Tumor, Adult trial opens near Boston, MA
We’ll email you when one opens near Boston, MA — at most once a week, no account needed, unsubscribe anytime.
Solid Tumor, Adult trials in other cities
Where these studies are running near Boston
Institutions with a site for the recruiting solid tumor, adult studies listed above.
- Dana-Farber Cancer Institute · 12 studies
- Massachusetts General Hospital · 7 studies
- Beth Israel Deaconess Medical Center · 3 studies
- Boston Children's Hospital · 2 studies
- Brigham and Women's Hospital · 2 studies
- Research Site · 2 studies
- Tufts Medical Center · 2 studies
- Avenzo Therapeutics Recruiting Site
What taking part in a solid tumor, adult study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting solid tumor, adult studies in Massachusetts.
Common questions
- Are there solid tumor, adult clinical trials near Boston?
- Yes. We're currently tracking 51 recruiting solid tumor, adult studies with a site near Boston, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor, adult study near Boston?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Boston to take part?
- Not necessarily. These studies have a site near Boston, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor, adult trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor, adult studies open near Boston regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.